U.S. markets close in 23 minutes

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.85+0.61 (+3.97%)
As of 03:37PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close15.24
Bid15.86 x 800
Ask15.86 x 800
Day's Range15.29 - 16.15
52 Week Range10.81 - 21.25
Avg. Volume968,385
Market Cap651.664M
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-2.20
Earnings DateNov 01, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ICPT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Intercept Pharmaceuticals, Inc.
    Analyst Report: Intercept Pharmaceuticals, Inc.Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
    Fair Value
    Economic Moat
    2 years agoMorningstar
View more
  • Zacks

    Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why

    Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.

  • Benzinga

    Intercept Pharma Summarizes Key Actions in Strategic Financial Repositioning

    Intercept Pharmaceuticals Inc (NASDAQ: ICPT) announced a summary of its actions to improve its capital position, including the recently announced private repurchases of senior secured convertible notes. Intercept is a biopharmaceutical company focused on developing and commercializing therapeutics for progressive non-viral liver diseases, including primary biliary cholangitis and nonalcoholic steatohepatitis. Related: Intercept Settles Ocaliva Litigation With Reddy's Lab. Intercept has been able

  • GlobeNewswire

    Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning

    Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million Company well-positioned to drive continued growth in PBC, progress NASH program, expand and advance pipeline MORRISTOWN, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced a summary of t